← Statins × cardiovascular events

TrialStroke2008

Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.

Larry B Goldstein et al.PubMed ↗Publisher ↗

  • Atorvastatin 80 mg dailylooks good hereFewer major cardiac events, fewer major cardiovascular events, lower revascularization procedures.Weak evidence: one subgroup, may be chance.

What the trial testedrandomised · 2,823 people · 2008

Randomised comparison

Reduced cardiovascular events

−46%−59% to −28%

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.54, 95% CI 0.41–0.72

One subgroup · may be chance

May have reduced major cardiac events in men

−39%−58% to −13%

atorvastatin 80 mg daily vs placebo, in men

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.61, 95% CI 0.42–0.87

One subgroup · may be chance

May have reduced major cardiovascular events in men

−22%−35% to −7%

atorvastatin 80 mg daily vs placebo, in men

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.78, 95% CI 0.65–0.93

One subgroup · may be chance

May have lowered revascularization procedures in men

−50%−63% to −33%

atorvastatin 80 mg daily vs placebo, in men

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.50, 95% CI 0.37–0.67

+5 more in the walkthrough ↓

Who was studied, and how

2,823people with dyslipidemia, in this paper

Among men, the trial randomly assignedassigned by chance

atorvastatin 80 mg daily
placebo

May have reduced major cardiac events−39%

May have reduced major cardiovascular events−22%

randomised · one subgroup, may be chance

Among women, the trial randomly assignedassigned by chance

atorvastatin 80 mg daily
placebo

No clear effect on combined risk of nonfatal and fatal stroke−16%

No clear effect on major cardiovascular events−16%

randomised

the abstract, start to end

… fatal stroke (treatment Hazard Ratio, HR=0.84, 95% CI 0.68, 1.02 in men versus HR=0.84, 95% CI 0.63, 1.11 in women; treatment x sex interaction P=0.99), major cardiac events (HR=0.61, 95% CI 0.42, 0.87 in men versus HR=0.76, 95% CI 0.48, 1.21 in women; P=0.45), major cardiovascular events (HR=0.78, 95% CI 0.65, 0.93 in men versus HR=0.84, 95% CI 0.65, 1.07 in women; P=0.63), revascularization procedures (HR=0.50, 95% CI 0.37, 0.67 in men versus HR=0.76, 95% CI 0.46, 1.24 in women; P=0.17), or any CHD event (HR=0.54, 95% CI 0.41, 0.72 in men …

← favours treatmentfavours comparator →
could be chance
Combined risk of nonfatal and fatal strokeatorvastatin 80 mg daily vs placebo, in men
HR 0.840.68–1.02
Combined risk of nonfatal and fatal strokeatorvastatin 80 mg daily vs placebo, in women
HR 0.840.63–1.11
Major cardiovascular eventsatorvastatin 80 mg daily vs placebo, in women
HR 0.840.65–1.07
Major cardiac eventsatorvastatin 80 mg daily vs placebo, in men
HR 0.610.42–0.87
Major cardiac eventsatorvastatin 80 mg daily vs placebo, in women
HR 0.760.48–1.21
Cardiovascular eventsatorvastatin 80 mg daily vs placebo
HR 0.760.46–1.24
Major cardiovascular eventsatorvastatin 80 mg daily vs placebo, in men
HR 0.780.65–0.93
Revascularization proceduresatorvastatin 80 mg daily vs placebo, in men
HR 0.500.37–0.67
Cardiovascular events
HR 0.540.41–0.72
StatinsCardiac procedures & devicesCardiovascular events

Statins × cardiovascular eventshelps?replicated

unlikelylikely
0.860.86 without it

Cardiac procedures & devices × cardiovascular eventshelps?mixed

unlikelylikely
0.500.40 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

19 papers cite it

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 18617654